Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model

被引:10
|
作者
Crepey, Pascal [1 ]
Boiron, Louis [2 ]
Araujo, Rafael Rodrigo [2 ]
Lopez, Juan Guillermo [3 ]
Petitjean, Audrey [4 ]
de Albuquerque Luna, Expedito Jose [5 ]
机构
[1] Univ Rennes, Dept Quantitat Methods Publ Hlth, UPRES EA Reperes 7449, EHESP, 15 Av Prof, F-35043 Rennes, France
[2] Sanofi Pasteur, Av Nacoes Unidas,14410 Condominio Parque, BR-04794000 Sao Paulo, SP, Brazil
[3] Sanofi Pasteur, Av Univ 1738, Ciudad De Mexico 04000, Cdmx, Mexico
[4] Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, France
[5] Univ Sao Paulo, Inst Trop Med IMT, Av Dr Eneas Carvalho Aguiar,470 Jardim Amer, BR-05403000 Sao Paulo, SP, Brazil
关键词
QIV; Quadrivalent; Public health; Cost-effectiveness; Vaccine; Influenza; Brazil; PUBLIC-HEALTH IMPACT; SEASONAL INFLUENZA; BURDEN;
D O I
10.1186/s12889-020-09409-7
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Influenza epidemics significantly weight on the Brazilian healthcare system and its society. Public health authorities have progressively expanded recommendations for vaccination against influenza, particularly to the pediatric population. However, the potential mismatch between the trivalent influenza vaccine (TIV) strains and those circulating during the season remains an issue. Quadrivalent vaccines improves vaccines effectiveness by preventing any potential mismatch on influenza B lineages. Methods We evaluate the public health and economic benefits of the switch from TIV to QIV for the pediatric influenza recommendation (6mo-5yo) by using a dynamic epidemiological model able to consider the indirect impact of vaccination. Results of the epidemiological model are then imputed in a health-economic model adapted to the Brazilian context. We perform deterministic and probabilistic sensitivity analysis to account for both epidemiological and economical sources of uncertainty. Results Our results show that switching from TIV to QIV in the Brazilian pediatric population would prevent 406,600 symptomatic cases, 11,300 hospitalizations and almost 400 deaths by influenza season. This strategy would save 3400 life-years yearly for an incremental direct cost of R$169 million per year, down to R$86 million from a societal perspective. Incremental cost-effectiveness ratios for the switch would be R$49,700 per life-year saved and R$26,800 per quality-adjusted life-year gained from a public payer perspective, and even more cost-effective from a societal perspective. Our results are qualitatively similar in our sensitivity analysis. Conclusions Our analysis shows that switching from TIV to QIV to protect children aged 6mo to 5yo in the Brazilian influenza epidemiological context could have a strong public health impact and represent a cost-effective strategy from a public payer perspective, and a highly cost-effective one from a societal perspective.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF QUADRIVALENT VERSUS TRIVALENT INFLUENZA VACCINATION IN GERMANY - LINKING A DYNAMIC TRANSMISSION MODEL WITH HEALTH AND ECONOMIC OUTCOMES
    Dolk, F. C.
    Eichner, M.
    Welte, R.
    Anastassopoulou, A.
    Van Bellinghen, L.
    Nautrup, Poulsen B.
    Van Vlaenderen, I
    Schmidt-Ott, R.
    Schwehm, M.
    Postma, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A339 - A339
  • [32] The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines
    Nichol, KL
    [J]. VACCINE, 2003, 21 (16) : 1769 - 1775
  • [33] Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy
    Mennini, Francesco Saverio
    Bini, Chiara
    Marcellusi, Andrea
    Rinaldi, Alessandro
    Franco, Elisabetta
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1867 - 1873
  • [34] Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program
    Zeevat, Florian
    Crepey, Pascal
    Dolk, F. Christiaan K.
    Postma, Arjan J.
    Breeveld-Dwarkasing, Vidya N. A.
    Postma, Maarten J.
    [J]. VALUE IN HEALTH, 2021, 24 (01) : 3 - 10
  • [35] COST-EFFECTIVENESS OF QUADRIVALENT VERSUS TRIVALENT INFLUENZA VACCINATION IN THE DUTCH NATIONAL INFLUENZA PREVENTION PROGRAM
    Zeevat, F.
    Crepey, P.
    Dolk, C.
    Postma, A. J.
    Breeveld-Dwarkasing, V. N. A.
    Postma, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S647 - S647
  • [36] Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines
    Weaver, M
    Krieger, J
    Castorina, J
    Walls, M
    Ciske, S
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (01) : 111 - 120
  • [37] Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States
    Clements, Karen M.
    Meier, Genevieve
    McGarry, Lisa J.
    Pruttivarasin, Narin
    Misurski, Derek A.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (05) : 1171 - 1180
  • [38] COST-EFFECTIVENESS ANALYSIS OF SWITCHING FROM A TRIVALENT TO A QUADRIVALENT INACTIVATED INFLUENZA VACCINE IN COLOMBIA
    Castro, R.
    Rueda, J. A.
    Drzewiecka, A.
    Gorecki, M.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S162 - S162
  • [39] Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
    Uruena, Analia
    Micone, Paula
    Magneres, Cecilia
    Mould-Quevedo, Joaquin
    Giglio, Norberto
    [J]. VACCINES, 2021, 9 (04)
  • [40] Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States
    de Boer, Pieter T.
    Crepey, Pascal
    Pitman, Richard J.
    Macabeo, Berengere
    Chit, Ayman
    Postma, Maarten J.
    [J]. VALUE IN HEALTH, 2016, 19 (08) : 964 - 975